Terpestacin is a bicyclo sesterpene produced by Arthrinium and other fungal species first reported in 1993 by Iimura and colleagues at the Bristol Myers Squibb Research Institute, Japan. Terpestacin inhibits syncytium formation induced by HIV infection. Terpestacin inhibits the growth of the phytopathogenic fungi, Alternaria brassicicola, Botrytis cinerea and Fusarium graminearum. Terpestacin inhibits angiogenesis via the ERK pathway and binds with UQCRB subunit of mitochondrial Complex III, resulting in inhibition of hypoxia-induced reactive oxygen species generation.